Tag: EGFR,In the News,NSCLC,Veristrat,blood-based cancer test,cancer diagnostics,lapatinib,letrozole,liquid biopsy,oncology,personalized medicine,serum protein test
-
Genetic Engineering News | Biodesix
The use of Biodesix’ predictive cancer therapy assay VeriStrat has been validated in a Phase III trial originally carried out to evaluate GlaxoSmithKline’s Tykerb®/Tyverb® (lapatinib) as an addition to Novartis’ Femara® (letrozole) in breast cancer patients. Data from the trial demonstrated that VeriStrat could be used to identify a group of patients with worse progression-free survival (PFS) when treated with Femara alone, independent of Her2…